Recombinant LIV-1 (Ladiratuzumab Biosimilar) antibody

Catalog No. ABIN7581553

The Human Monoclonal anti-LIV-1 (Ladiratuzumab Biosimilar) antibody has been validated for ELISA, BLI, FACS, Func and SPR. It is suitable to detect LIV-1 (Ladiratuzumab Biosimilar) in samples from Human.

Quick Overview for Recombinant LIV-1 (Ladiratuzumab Biosimilar) antibody (ABIN7581553)

Target: LIV-1 (Ladiratuzumab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Human

Clonality: Monoclonal

Conjugate: This LIV-1 (Ladiratuzumab Biosimilar) antibody is un-conjugated

Application: ELISA, Bio-Layer Interferometry (BLI), Flow Cytometry (FACS), Functional Studies (Func), Surface Plasmon Resonance (SPR)

Product Details anti-LIV-1 (Ladiratuzumab Biosimilar) Antibody

Expression System: CHO Cells

Purpose: Anti-LIV-1 / SLC39A6 Reference Antibody (ladiratuzumab)

Sequence: QVQLVQSGAE VKKPGASVKV SCKASGLTIE DYYMHWVRQA PGQGLEWMGW IDPENGDTEY GPKFQGRVTM TRDTSINTAY MELSRLRSDD TAVYYCAVHN AHYGTWFAYW GQGTLVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKKVEP KSCDKTHTCP PCPAPELLGG PSVFLFPPKP KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ VYTLPPSRDE LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPG,DVVMTQSPLS LPVTLGQPAS ISCRSSQSLL HSSGNTYLEW YQQRPGQSPR PLIYKISTRF SGVPDRFSGS GSGTDFTLKI SRVEAEDVGV YYCFQGSHVP YTFGGGTKVE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE VTHQGLSSPV TKSFNRGEC

Characteristics: Anti-LIV-1 / SLC39A6 Reference Antibody (ladiratuzumab) is expressed from CHO. The heavy chain type is huIgG1, and the light chain type is hukappa. It has a predicted MW of 145.5 kDa.

Purity: >95 %

Isotype: IgG1

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Comment:

Therapeutic Agents by Target and Mechanism: LIV-1 inhibitors

Restrictions: For Research Use only

Handling

Format: Lyophilized

Concentration: 1 mg/mL

Buffer: 25 mM histidine, 8 % sucrose, 0.01 % Tween80 pH 6.2

Storage: 4 °C,-80 °C

Storage Comment: +4°C,-80°C

Target Details for LIV-1 (Ladiratuzumab Biosimilar)

Target: LIV-1 (Ladiratuzumab Biosimilar)

Target Type: Biosimilar

Molecular Weight: 145.5 kDa

UniProt: Q13433